Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution

Abstract excerpt

For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development of drugs targeting ADAM17 has been harder than expected. This has generally been due to its multifunctionality, with...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HER2/EGFR in Cancer Research
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to Peptidase Inhibition and Analysis